Back to results

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Primary Purpose

Non-alcoholic Steatohepatitis

Status

Recruiting

Phase

Phase 2

Locations

International

Study Type

Interventional

Intervention

NNC0194 0499 50 mg/mL

Placebo (NNC0194-0499)

Semaglutide 3 mg/mL

Semaglutide placebo

NNC0174 0833 10 mg/mL

NNC0174 0833 placebo

About this trial

This is an interventional treatment trial for Non-alcoholic Steatohepatitis

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Aged greater than or equal to 18 years at the time of signing informed consent. In Republic of Korea, subjects must be aged greater than or equal to 19 years. In Japan, subjects must be aged greater than or equal to 20 years. In Singapore, subjects must be aged greater than or equal to 21 years.
Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to Visit 1.
Histological evidence of fibrosis stage 2, 3 or 4 according to the NASH CRN classification based on a central pathologist evaluation of the baseline liver biopsy.
Histological non-alcoholic fatty liver disease (NAFLD) activity score (NAS) greater than or equal to 4 for subjects with F2/F3 or greater than or equal to 3 for subjects with F4 based on a central pathologist evaluation of the baseline liver biopsy. All subjects must have a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning.

Exclusion Criteria:

Documented causes of chronic liver disease other than NAFLD.
Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).
Presence or history of ascites more than grade 1, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at V2A.
For subjects with F4, presence or history of gastro-oesophageal varices more than or equal to grade 2 at V3. An oesophagogastroduodenoscopy performed no more than 52 weeks prior to V3 must be available at V3.
Known or suspected excessive consumption of alcohol (more than 20 g/day for women or more than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).
Treatment with vitamin E (at doses more than or equal to 800 IU/day) or pioglitazone or medications approved for the treatment of NASH which has not been at a stable dose in the opinion of the investigator in the period from 90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until V2A.
Treatment with GLP-1 RAs within 90 days prior to V2A. Subjects with a historical liver biopsy taken more than 90 days prior to V2A are excluded if they receive treatment with GLP-1 RAs from time of biopsy until V2A.
Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until V2A.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Active Comparator

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

NNC0194-0499 7.5 mg + semaglutide 2.4 mg

Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg

NNC0194-0499 15 mg + semaglutide 2.4 mg

Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg

NNC0194-0499 30 mg + semaglutide 2.4 mg

NNC0194-0499 30 mg + semaglutide placebo 2.4 mg

Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg

Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg

NNC0174-0833 2.4 mg + semaglutide 2.4 mg

Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Outcomes

Primary Outcome Measures

Improvement in liver fibrosis and no worsening of NASH (Yes/No)

Count of subjects Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale

Secondary Outcome Measures

Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)

Count of subjects Resolution of steatohepatitis is defined as a NAS of 0-1 for inflammation, 0 for ballooning and any value for steatosis according to NASH CRN52. Fibrosis is graded on the NASH CRN (Non-Alcoholic Steatohepatitis Clinical Research Network) fibrosis scale from 0 to 4.

Improvement in steatohepatitis with at least a 2-point reduction in NAS and no worsening of fibrosis (Yes/No)

Count of subjects The 2-point reduction must include at least a 1-point reduction in either lobular inflammation or hepatocellular ballooning.

Change in histology-assessed liver collagen proportionate area

Ratio to baseline

Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No)

Count of subjects Resolution of steatohepatitis is defined as an NAS score of 0-1 for inflammation, 0 for ballooning and any value for steatosis (according to NASH CRN). Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale

Improvement in liver fibrosis (Yes/No)

Count of subjects Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale

Progression of liver fibrosis (Yes/No)

Count of subjects For subjects with fibrosis stage 2 or 3 at baseline

Worsening in steatohepatitis (Yes/No)

Count of subjects Worsening in steatohepatitis is defined as increase in NAS score for ballooning, inflammation or steatosis

Improvement in ballooning (Yes/No)

Count of subjects

Improvement in inflammation (Yes/No)

Count of subjects

Improvement in steatosis (Yes/No)

Count of subjects

Change in ALT (alanine aminotransferase)

Ratio to baseline

Change in AST (aspartate aminotransferase)

Ratio to baseline

Change in inflammation assessed by HsCRP (high sensitivity C-reactive protein)

Ratio to baseline

Change in ELF (Enhanced Liver Fibrosis) score

Logarithm

Change in HbA1c. For subjects with type 2 diabetes

%-points (absolute change)

Change in triglycerides

Ratio to baseline

Change in free fatty acids

Ratio to baseline

Change in LDL (low density lipoprotein) cholesterol

Ratio to baseline

Change in HDL (high density lipoprotein) cholesterol

Ratio to baseline

Relative change in body weight

Percentage

Change in SF-36 (36-item Short Form Survey) bodily pain

Points

Change in NASH-CHECK (patient-reported outcome measure for non-alcoholic steatohepatitis)pain

Points

Change in PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue score

Points

Number of treatment emergent adverse events (TEAEs)

Count

Full Information

NCT ID

NCT05016882

First Posted

August 18, 2021

Last Updated

October 24, 2023

Sponsor

Novo Nordisk A/S

1. Study Identification

Unique Protocol Identification Number

NCT05016882

Brief Title

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Official Title

Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial

Study Type

Interventional

2. Study Status

Record Verification Date

October 2023

Overall Recruitment Status

Recruiting

Study Start Date

August 31, 2021 (Actual)

Primary Completion Date

May 8, 2024 (Anticipated)

Study Completion Date

March 12, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

5. Study Description

Brief Summary

This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH). NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499. The 2 medicines may work better together than on their own. The study will also look at a combination of semaglutide and another weight-loss medicine called NNC0174-0833, which may be another treatment option for NASH. Each week, participants will get 2 injections. These could be 2 of the 3 medicines OR 1 of the medicines and a placebo OR 2 placebo injections. Which treatment participants get is decided by chance. A placebo is a dummy medicine which looks like the real medicine but doesn't contain any active medicine. The study will last for about 19 months. Participants will have 14 clinic visits and 9 phone calls with the study doctor. Participants will have 1 or 2 liver biopsies (tiny pieces of liver tissue) - one at the start (if participants have not had a biopsy recently) and one at the end of the study treatment. Women: Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Non-alcoholic Steatohepatitis

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Model Description

This is a randomised, double-blind, active and placebo-controlled, double-dummy, parallel group, multinational trial investigating NNC0194-0499 at 3 different dose levels when co administered with semaglutide

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

672 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

NNC0194-0499 7.5 mg + semaglutide 2.4 mg

Arm Type

Experimental

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Arm Title

Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg

Arm Type

Placebo Comparator

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Arm Title

NNC0194-0499 15 mg + semaglutide 2.4 mg

Arm Type

Experimental

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Arm Title

Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg

Arm Type

Placebo Comparator

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Arm Title

NNC0194-0499 30 mg + semaglutide 2.4 mg

Arm Type

Experimental

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Arm Title

NNC0194-0499 30 mg + semaglutide placebo 2.4 mg

Arm Type

Experimental

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Arm Title

Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg

Arm Type

Active Comparator

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Arm Title

Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg

Arm Type

Placebo Comparator

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Arm Title

NNC0174-0833 2.4 mg + semaglutide 2.4 mg

Arm Type

Experimental

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Arm Title

Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg

Arm Type

Placebo Comparator

Arm Description

Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.

Intervention Type

Drug

Intervention Name(s)

NNC0194 0499 50 mg/mL

Intervention Description

Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months

Intervention Type

Drug

Intervention Name(s)

Placebo (NNC0194-0499)

Intervention Description

Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months

Intervention Type

Drug

Intervention Name(s)

Semaglutide 3 mg/mL

Intervention Description

Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months

Intervention Type

Drug

Intervention Name(s)

Semaglutide placebo

Intervention Description

Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months

Intervention Type

Drug

Intervention Name(s)

NNC0174 0833 10 mg/mL

Intervention Description

Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months

Intervention Type

Drug

Intervention Name(s)

NNC0174 0833 placebo

Intervention Description

Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months

Primary Outcome Measure Information:

Title

Improvement in liver fibrosis and no worsening of NASH (Yes/No)

Description

Count of subjects Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale

Time Frame

From baseline (week 0) to week 52

Secondary Outcome Measure Information:

Title

Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)

Description

Time Frame

From baseline (week 0) to week 52

Title

Improvement in steatohepatitis with at least a 2-point reduction in NAS and no worsening of fibrosis (Yes/No)

Description

Count of subjects The 2-point reduction must include at least a 1-point reduction in either lobular inflammation or hepatocellular ballooning.

Time Frame

From baseline (week 0) to week 52

Title

Change in histology-assessed liver collagen proportionate area

Description

Ratio to baseline

Time Frame

From baseline (week 0) to week 52

Title

Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No)

Description

Time Frame

From baseline (week 0) to week 52

Title

Improvement in liver fibrosis (Yes/No)

Description

Count of subjects Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale

Time Frame

From baseline (week 0) to week 52

Title

Progression of liver fibrosis (Yes/No)

Description

Count of subjects For subjects with fibrosis stage 2 or 3 at baseline

Time Frame

From baseline (week 0) to week 52

Title

Worsening in steatohepatitis (Yes/No)

Description

Count of subjects Worsening in steatohepatitis is defined as increase in NAS score for ballooning, inflammation or steatosis

Time Frame

From baseline (week 0) to week 52

Title

Improvement in ballooning (Yes/No)

Description

Count of subjects

Time Frame

From baseline (week 0) to week 52

Title

Improvement in inflammation (Yes/No)

Description

Count of subjects

Time Frame

From baseline (week 0) to week 52

Title

Improvement in steatosis (Yes/No)

Description

Count of subjects

Time Frame

From baseline (week 0) to week 52

Title

Change in ALT (alanine aminotransferase)

Description

Ratio to baseline

Time Frame

From baseline (week 0) to week 52

Title

Change in AST (aspartate aminotransferase)

Description

Ratio to baseline

Time Frame

From baseline (week 0) to week 52

Title

Change in inflammation assessed by HsCRP (high sensitivity C-reactive protein)

Description

Ratio to baseline

Time Frame

From baseline (week 0) to week 52

Title

Change in ELF (Enhanced Liver Fibrosis) score

Description

Logarithm

Time Frame

From baseline (week 0) to week 52

Title

Change in HbA1c. For subjects with type 2 diabetes

Description

%-points (absolute change)

Time Frame

From baseline (week 0) to week 52

Title

Change in triglycerides

Description

Ratio to baseline

Time Frame

From baseline (week 0) to week 52

Title

Change in free fatty acids

Description

Ratio to baseline

Time Frame

From baseline (week 0) to week 52

Title

Change in LDL (low density lipoprotein) cholesterol

Description

Ratio to baseline

Time Frame

From baseline (week 0) to week 52

Title

Change in HDL (high density lipoprotein) cholesterol

Description

Ratio to baseline

Time Frame

From baseline (week 0) to week 52

Title

Relative change in body weight

Description

Percentage

Time Frame

From baseline (week 0) to week 52

Title

Change in SF-36 (36-item Short Form Survey) bodily pain

Description

Points

Time Frame

From baseline (week 0) to week 52

Title

Change in NASH-CHECK (patient-reported outcome measure for non-alcoholic steatohepatitis)pain

Description

Points

Time Frame

From baseline (week 0) to week 52

Title

Change in PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue score

Description

Points

Time Frame

From baseline (week 0) to week 52

Title

Number of treatment emergent adverse events (TEAEs)

Description

Count

Time Frame

From baseline (week 0) to week 59

10. Eligibility

Sex

All

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Aged greater than or equal to 18 years at the time of signing informed consent. In Republic of Korea, subjects must be aged greater than or equal to 19 years. In Japan, subjects must be aged greater than or equal to 20 years. In Singapore, subjects must be aged greater than or equal to 21 years. Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to Visit 1. Histological evidence of fibrosis stage 2, 3 or 4 according to the NASH CRN classification based on a central pathologist evaluation of the baseline liver biopsy. Histological non-alcoholic fatty liver disease (NAFLD) activity score (NAS) greater than or equal to 4 for subjects with F2/F3 or greater than or equal to 3 for subjects with F4 based on a central pathologist evaluation of the baseline liver biopsy. All subjects must have a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning. Exclusion Criteria: Documented causes of chronic liver disease other than NAFLD. Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A). Presence or history of ascites more than grade 1, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at V2A. For subjects with F4, presence or history of gastro-oesophageal varices more than or equal to grade 2 at V3. An oesophagogastroduodenoscopy performed no more than 52 weeks prior to V3 must be available at V3. Known or suspected excessive consumption of alcohol (more than 20 g/day for women or more than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)). Treatment with vitamin E (at doses more than or equal to 800 IU/day) or pioglitazone or medications approved for the treatment of NASH which has not been at a stable dose in the opinion of the investigator in the period from 90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until V2A. Treatment with GLP-1 RAs within 90 days prior to V2A. Subjects with a historical liver biopsy taken more than 90 days prior to V2A are excluded if they receive treatment with GLP-1 RAs from time of biopsy until V2A. Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until V2A.

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Novo Nordisk

Phone

(+1) 866-867-7178

clinicaltrials@novonordisk.com

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Clinical Transparency (dept. 1452)

Organizational Affiliation

Novo Nordisk A/S

Official's Role

Study Director

Facility Information:

Facility Name

Novo Nordisk Investigational Site

City

Huntsville

State/Province

Alabama

ZIP/Postal Code

35801

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Chandler

State/Province

Arizona

ZIP/Postal Code

85224

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Peoria

State/Province

Arizona

ZIP/Postal Code

85381

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85715

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Canoga Park

State/Province

California

ZIP/Postal Code

91303

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

La Jolla

State/Province

California

ZIP/Postal Code

92037

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Lancaster

State/Province

California

ZIP/Postal Code

93534

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Long Beach

State/Province

California

ZIP/Postal Code

90808

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Redwood City

State/Province

California

ZIP/Postal Code

94063

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Sacramento

State/Province

California

ZIP/Postal Code

95817

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Colorado Springs

State/Province

Colorado

ZIP/Postal Code

80907

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Hartford

State/Province

Connecticut

ZIP/Postal Code

06106

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Doral

State/Province

Florida

ZIP/Postal Code

33122

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Hialeah

State/Province

Florida

ZIP/Postal Code

33012

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Inverness

State/Province

Florida

ZIP/Postal Code

34452

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Jacksonville

State/Province

Florida

ZIP/Postal Code

32224

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Lakewood Ranch

State/Province

Florida

ZIP/Postal Code

34211

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Maitland

State/Province

Florida

ZIP/Postal Code

32751

Country

United States

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33135

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33136

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Sarasota

State/Province

Florida

ZIP/Postal Code

34240

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Viera E.

State/Province

Florida

ZIP/Postal Code

32940

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Zephyrhills

State/Province

Florida

ZIP/Postal Code

33542

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Atlanta

State/Province

Georgia

ZIP/Postal Code

30309

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Macon

State/Province

Georgia

ZIP/Postal Code

31201

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Marietta

State/Province

Georgia

ZIP/Postal Code

30060

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Snellville

State/Province

Georgia

ZIP/Postal Code

30078

Country

United States

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Idaho Falls

State/Province

Idaho

ZIP/Postal Code

83404-7590

Country

United States

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

South Bend

State/Province

Indiana

ZIP/Postal Code

46635

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kansas City

State/Province

Kansas

ZIP/Postal Code

66160

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Topeka

State/Province

Kansas

ZIP/Postal Code

66606

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Houma

State/Province

Louisiana

ZIP/Postal Code

70363

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Marrero

State/Province

Louisiana

ZIP/Postal Code

70072

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Metairie

State/Province

Louisiana

ZIP/Postal Code

70006

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Shreveport

State/Province

Louisiana

ZIP/Postal Code

71105

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Baltimore

State/Province

Maryland

ZIP/Postal Code

21202

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Bethesda

State/Province

Maryland

ZIP/Postal Code

20889

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Detroit

State/Province

Michigan

ZIP/Postal Code

48202

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kansas City

State/Province

Missouri

ZIP/Postal Code

64131

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Omaha

State/Province

Nebraska

ZIP/Postal Code

68198-3020

Country

United States

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Florham Park

State/Province

New Jersey

ZIP/Postal Code

07932

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10016

Country

United States

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10016

Country

United States

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

New York

State/Province

New York

ZIP/Postal Code

10065

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44106

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43210

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Springboro

State/Province

Ohio

ZIP/Postal Code

45066

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Danville

State/Province

Pennsylvania

ZIP/Postal Code

17822-2111

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Hershey

State/Province

Pennsylvania

ZIP/Postal Code

17033

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19104

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19107-5244

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15213

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Hermitage

State/Province

Tennessee

ZIP/Postal Code

37076

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Nashville

State/Province

Tennessee

ZIP/Postal Code

37211

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Arlington

State/Province

Texas

ZIP/Postal Code

76012

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75203

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77030

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77058

Country

United States

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Houston

State/Province

Texas

ZIP/Postal Code

77089

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Round Rock

State/Province

Texas

ZIP/Postal Code

78681

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

San Antonio

State/Province

Texas

ZIP/Postal Code

78215

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Waco

State/Province

Texas

ZIP/Postal Code

76710

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Wichita Falls

State/Province

Texas

ZIP/Postal Code

76301

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Falls Church

State/Province

Virginia

ZIP/Postal Code

22042

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Richmond

State/Province

Virginia

ZIP/Postal Code

23226

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Roanoke

State/Province

Virginia

ZIP/Postal Code

24014

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Seattle

State/Province

Washington

ZIP/Postal Code

98104

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Seattle

State/Province

Washington

ZIP/Postal Code

98105

Country

United States

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Broadmeadow

State/Province

New South Wales

ZIP/Postal Code

2292

Country

Australia

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Darlinghurst

State/Province

New South Wales

ZIP/Postal Code

2010

Country

Australia

Individual Site Status

Suspended

Facility Name

Novo Nordisk Investigational Site

City

Kingswood

State/Province

New South Wales

ZIP/Postal Code

2747

Country

Australia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Westmead

State/Province

New South Wales

ZIP/Postal Code

2145

Country

Australia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Adelaide

State/Province

South Australia

ZIP/Postal Code

5000

Country

Australia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Clayton

State/Province

Victoria

ZIP/Postal Code

3168

Country

Australia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Fitzroy

State/Province

Victoria

ZIP/Postal Code

3065

Country

Australia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Heidelberg

State/Province

Victoria

ZIP/Postal Code

3084

Country

Australia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Melbourne

State/Province

Victoria

ZIP/Postal Code

3004

Country

Australia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Murdoch

State/Province

Western Australia

ZIP/Postal Code

6150

Country

Australia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Bruxelles

ZIP/Postal Code

1070

Country

Belgium

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Bruxelles

ZIP/Postal Code

1200

Country

Belgium

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Edegem

ZIP/Postal Code

2650

Country

Belgium

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Gent

ZIP/Postal Code

9000

Country

Belgium

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Panagyurishte

ZIP/Postal Code

4500

Country

Bulgaria

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Plovdiv

ZIP/Postal Code

4002

Country

Bulgaria

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Sofia

ZIP/Postal Code

1407

Country

Bulgaria

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Sofia

ZIP/Postal Code

1431

Country

Bulgaria

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Sofia

ZIP/Postal Code

1504

Country

Bulgaria

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Sofia

ZIP/Postal Code

1527

Country

Bulgaria

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Sofia

ZIP/Postal Code

1618

Country

Bulgaria

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Calgary

State/Province

Alberta

ZIP/Postal Code

T2N 4Z6

Country

Canada

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Vancouver

State/Province

British Columbia

ZIP/Postal Code

V6Z 2K5

Country

Canada

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Halifax

State/Province

Nova Scotia

ZIP/Postal Code

B3H 2Y9

Country

Canada

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

London

State/Province

Ontario

ZIP/Postal Code

N6A 2C2

Country

Canada

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M6H 3M1

Country

Canada

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H4A 3J1

Country

Canada

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Terrebonne

State/Province

Quebec

ZIP/Postal Code

J6X 4P7

Country

Canada

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Liberec

ZIP/Postal Code

460 63

Country

Czechia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Plzen

ZIP/Postal Code

301 00

Country

Czechia

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Prague 2

ZIP/Postal Code

128 08

Country

Czechia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Hvidovre

ZIP/Postal Code

2650

Country

Denmark

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

København NV

ZIP/Postal Code

2400

Country

Denmark

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Odense C

ZIP/Postal Code

5000

Country

Denmark

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Angers

ZIP/Postal Code

49100

Country

France

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Clichy

ZIP/Postal Code

92110

Country

France

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Lille

ZIP/Postal Code

59037

Country

France

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Lyon Cedex 4

ZIP/Postal Code

69317

Country

France

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Nice

ZIP/Postal Code

06200

Country

France

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Paris

ZIP/Postal Code

75013

Country

France

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Saint Herblain

ZIP/Postal Code

44800

Country

France

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Venissieux

ZIP/Postal Code

69200

Country

France

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Essen

ZIP/Postal Code

45147

Country

Germany

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Lübeck

ZIP/Postal Code

23562

Country

Germany

Individual Site Status

Active, not recruiting

Facility Name

Novo Nordisk Investigational Site

City

Mainz

ZIP/Postal Code

55131

Country

Germany

Individual Site Status

Active, not recruiting

Facility Name

Novo Nordisk Investigational Site

City

Tübingen

ZIP/Postal Code

72076

Country

Germany

Individual Site Status

Active, not recruiting

Facility Name

Novo Nordisk Investigational Site

City

Würzburg

ZIP/Postal Code

97080

Country

Germany

Individual Site Status

Active, not recruiting

Facility Name

Novo Nordisk Investigational Site

City

Athens

ZIP/Postal Code

GR-11527

Country

Greece

Individual Site Status

Active, not recruiting

Facility Name

Novo Nordisk Investigational Site

City

Goudi, Athens

ZIP/Postal Code

GR-115 27

Country

Greece

Individual Site Status

Active, not recruiting

Facility Name

Novo Nordisk Investigational Site

City

Thessaloniki

ZIP/Postal Code

GR-54621

Country

Greece

Individual Site Status

Active, not recruiting

Facility Name

Novo Nordisk Investigational Site

City

Thessaloniki

ZIP/Postal Code

GR-54642

Country

Greece

Individual Site Status

Active, not recruiting

Facility Name

Novo Nordisk Investigational Site

City

Thessaloniki

ZIP/Postal Code

GR-54642

Country

Greece

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Secunderabad

State/Province

Andhra Pradesh

ZIP/Postal Code

500003

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Surat

State/Province

Gujarat

ZIP/Postal Code

395002

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Surat

State/Province

Gujarat

ZIP/Postal Code

395009

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Gurugram

State/Province

Haryana

ZIP/Postal Code

122001

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Mangalore

State/Province

Karnataka

ZIP/Postal Code

575001

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Belgaum

State/Province

Karnatka

ZIP/Postal Code

590010

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Mumbai

State/Province

Maharashtra

ZIP/Postal Code

400012

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Mumbai

State/Province

Maharashtra

ZIP/Postal Code

400012

Country

India

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Nagpur

State/Province

Maharashtra

ZIP/Postal Code

440010

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

New Dehli

State/Province

New Delhi

ZIP/Postal Code

110029

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Chandigarh,

State/Province

Punjab

ZIP/Postal Code

160062

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Chandigarh

State/Province

Punjab

ZIP/Postal Code

160012

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Ludhiana

State/Province

Punjab

ZIP/Postal Code

141001

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Jaipur

State/Province

Rajasthan

ZIP/Postal Code

302001

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Jaipur

State/Province

Rajasthan

ZIP/Postal Code

302004

Country

India

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Hyderabad

State/Province

Telagana

ZIP/Postal Code

500012

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Hyderabad

State/Province

Telangana

ZIP/Postal Code

500072

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

New Delhi

ZIP/Postal Code

110070

Country

India

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Ancona

ZIP/Postal Code

60126

Country

Italy

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Bergamo

ZIP/Postal Code

24127

Country

Italy

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Bologna

ZIP/Postal Code

40138

Country

Italy

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Firenze

ZIP/Postal Code

50134

Country

Italy

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Padova

ZIP/Postal Code

35128

Country

Italy

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Pisa

ZIP/Postal Code

56124

Country

Italy

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Roma

ZIP/Postal Code

00168

Country

Italy

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Rome

ZIP/Postal Code

00128

Country

Italy

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Chiba-shi, Chiba

ZIP/Postal Code

260-8677

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Fukui-shi, Fukui

ZIP/Postal Code

918-8503

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Hamamatsu-shi, Shizuoka

ZIP/Postal Code

431-3192

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Hatsukaichi-shi, Hiroshima

ZIP/Postal Code

783-8503

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kamigyo-ku, Kyoto

ZIP/Postal Code

602-8566

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kawasaki-shi, Kanagawa

ZIP/Postal Code

216-8511

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kumamoto-shi, Kumamoto

ZIP/Postal Code

862-8655

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Minato-ku, Tokyo

ZIP/Postal Code

105-8470

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Okayama-shi, Okayama

ZIP/Postal Code

700-8505

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Saga-shi, Saga

ZIP/Postal Code

849-8501

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Sendai-shi, Miyagi

ZIP/Postal Code

980-0873

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Suita-shi, Osaka

ZIP/Postal Code

564-0013

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Toon-shi, Ehime

ZIP/Postal Code

791-0295

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Wakayama-shi, Wakayama

ZIP/Postal Code

640-8158

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Yokohama-shi, Kanagawa

ZIP/Postal Code

236-0004

Country

Japan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Ansan

State/Province

Gyeonggi-do

ZIP/Postal Code

15355

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Daegu

ZIP/Postal Code

41944

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Daegu

ZIP/Postal Code

42415

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Daegu

ZIP/Postal Code

42601

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Gangwon-do

ZIP/Postal Code

26426

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Gyeonggi-do

ZIP/Postal Code

14584

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Seoul

ZIP/Postal Code

03722

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Seoul

ZIP/Postal Code

06973

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Seoul

ZIP/Postal Code

07061

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Seoul

ZIP/Postal Code

08308

Country

Korea, Republic of

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kota Bharu

State/Province

Kelantan

ZIP/Postal Code

16150

Country

Malaysia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Batu Caves

ZIP/Postal Code

68100

Country

Malaysia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kuala Lumpur

ZIP/Postal Code

59100

Country

Malaysia

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Bydgoszcz

ZIP/Postal Code

85-605

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Katowice

ZIP/Postal Code

40-156

Country

Poland

Individual Site Status

Suspended

Facility Name

Novo Nordisk Investigational Site

City

Katowice

ZIP/Postal Code

40-752

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Krakow

ZIP/Postal Code

31-501

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kraków

ZIP/Postal Code

31-156

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Mysłowice

ZIP/Postal Code

41-400

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Rzeszow

ZIP/Postal Code

35-326

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Wroclaw

ZIP/Postal Code

50-088

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Wroclaw

ZIP/Postal Code

50-220

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Wroclaw

ZIP/Postal Code

51-162

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Staszow

State/Province

Świętokrzyskie

ZIP/Postal Code

28-200

Country

Poland

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Lisboa

ZIP/Postal Code

1649-035

Country

Portugal

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Matosinhos

ZIP/Postal Code

4464-513

Country

Portugal

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Vila Nova de Gaia

ZIP/Postal Code

4400-346

Country

Portugal

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

San Juan

ZIP/Postal Code

00927

Country

Puerto Rico

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Arkhangelsk

ZIP/Postal Code

163001

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Barnaul

ZIP/Postal Code

656045

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Ekaterinburg

ZIP/Postal Code

620075

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Izhevsk

ZIP/Postal Code

426061

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Kazan

ZIP/Postal Code

420012

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Kazan

ZIP/Postal Code

420111

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Moscow

ZIP/Postal Code

117041

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Moscow

ZIP/Postal Code

117292

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Moscow

ZIP/Postal Code

119435

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Moscow

ZIP/Postal Code

125367

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Moscow

ZIP/Postal Code

129226

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Novosibirsk

ZIP/Postal Code

630005

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Novosibirsk

ZIP/Postal Code

630089

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Novosibirsk

ZIP/Postal Code

630099

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Omsk

ZIP/Postal Code

644024

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Omsk

ZIP/Postal Code

644029

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Penza

ZIP/Postal Code

440052

Country

Russian Federation

Individual Site Status

Completed

Facility Name

Novo Nordisk Investigational Site

City

Saint Petersburg

ZIP/Postal Code

190013

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Saint Petersburg

ZIP/Postal Code

192283

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Saint Petersburg

ZIP/Postal Code

196084

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Saint-Petersburg

ZIP/Postal Code

194044

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Saint-Petersburg

ZIP/Postal Code

194156

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Saint-Petersburg

ZIP/Postal Code

194358

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Saint-Petersburg

ZIP/Postal Code

195067

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Saint-Petersburg

ZIP/Postal Code

196143

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Saint-Petersburg

ZIP/Postal Code

196603

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Saint-Petersburg

ZIP/Postal Code

197110

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Tomsk

ZIP/Postal Code

634050

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Ulianovsk

ZIP/Postal Code

432063

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Yoshkar-Ola

ZIP/Postal Code

424004

Country

Russian Federation

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Singapore

ZIP/Postal Code

119228

Country

Singapore

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Singapore

ZIP/Postal Code

169608

Country

Singapore

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Singapore

ZIP/Postal Code

529889

Country

Singapore

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Barcelona

ZIP/Postal Code

08035

Country

Spain

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Majadahonda

ZIP/Postal Code

28222

Country

Spain

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Pontevedra

ZIP/Postal Code

36004

Country

Spain

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Santander

ZIP/Postal Code

39008

Country

Spain

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Sevilla

ZIP/Postal Code

41013

Country

Spain

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Valladolid

ZIP/Postal Code

47010

Country

Spain

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Chiayi City

ZIP/Postal Code

600

Country

Taiwan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kaoshiung

ZIP/Postal Code

807

Country

Taiwan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Tainan

ZIP/Postal Code

704

Country

Taiwan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Taipei

ZIP/Postal Code

100

Country

Taiwan

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Adana

ZIP/Postal Code

01000

Country

Turkey

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Ankara

ZIP/Postal Code

06230

Country

Turkey

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Ankara

ZIP/Postal Code

06500

Country

Turkey

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

Gaziantep

ZIP/Postal Code

27070

Country

Turkey

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34093

Country

Turkey

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34098

Country

Turkey

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Istanbul

ZIP/Postal Code

34899

Country

Turkey

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Kocaeli

ZIP/Postal Code

41000

Country

Turkey

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Rize

ZIP/Postal Code

53020

Country

Turkey

Individual Site Status

Recruiting

Facility Name

Novo Nordisk Investigational Site

City

Birmingham

ZIP/Postal Code

B15 2TH

Country

United Kingdom

Individual Site Status

Withdrawn

Facility Name

Novo Nordisk Investigational Site

City

Exeter

ZIP/Postal Code

EX2 5DW

Country

United Kingdom

Individual Site Status

Not yet recruiting

Facility Name

Novo Nordisk Investigational Site

City

London

ZIP/Postal Code

W2 1NY

Country

United Kingdom

Individual Site Status

Withdrawn

12. IPD Sharing Statement

Plan to Share IPD

Yes

IPD Sharing Plan Description

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

IPD Sharing URL

http://novonordisk-trials.com

Learn more about this trial

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

We'll reach out to this number within 24 hrs

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm 9

Arm 10

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial